Genetic Factors in Lung Cancer Risk Related to Debrisoquine Metabolism
Author Information
Author(s): M.R. Law, M.R. Hetzel, J.R. Idle
Primary Institution: St Bartholomew's Hospital Medical College
Hypothesis
Is there a genetic predisposition to lung cancer based on debrisoquine metabolism?
Conclusion
Fewer lung cancer cases than controls were poor metabolisers of debrisoquine, suggesting a genetic predisposition to smoking-related lung cancer.
Supporting Evidence
- 1.9% of lung cancer cases were poor metabolisers compared to 8.7% of controls.
- Poor metabolisers have one-fifth the risk of smoking-related lung cancer compared to extensive metabolisers.
- Statistical significance was greater when a larger control group was used.
Takeaway
Some people process a drug called debrisoquine differently because of their genes, and this can affect their risk of getting lung cancer from smoking.
Methodology
A case-control study comparing debrisoquine metabolism in lung cancer patients and matched controls.
Potential Biases
No apparent sources of bias were identified that could explain the association.
Limitations
The study was limited to a specific population and may not generalize to all ethnic groups.
Participant Demographics
Caucasian inpatients with newly diagnosed lung cancer and matched controls.
Statistical Information
P-Value
0.03
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website